Neuropsychological deficits in nonsmokers with schizophrenia: Effects of a nicotinic antagonist

Sacco, Kristi A.; Termine, Angelo; Dudas, Melissa M.; Seyal, Aisha A.; Allen, Terrence K.; Vessicchio, Jennifer C.; Wexler, Bruce E.; George, Tony P.

doi:10.1016/j.schres.2006.03.025

Cited by 23 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since treatment and rehabilitative outcomes in schizophrenia have been associated with severity of baseline neurocognitive impairment (Green, 1996), smoking status should be considered as a potential predictor of treatment outcome in future studies in schizophrenia. However, given our small subgroup sample sizes and that the data are derived from a secondary analysis of baseline data from larger prospective laboratory studies of the effects of smoking and cognition in schizophrenia (Sacco et al, 2005; Sacco et al, 2006) our findings should be considered preliminary and in need of replication using larger samples.…”

Section: Discussionmentioning

confidence: 95%

“…Whether these subjects would obtain cognitive enhancement from nicotine or nicotine-like pharmacotherapies is an open question. Studies in non-smokers with schizophrenia (including former and never-smokers) have reported that the cognitive deficits in these patients are insensitive to treatment with the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (Sacco et al, 2006) but that nicotine replacement therapy can improve some aspects of cognitive performance (CPT, SCWT and episodic memory) (Barr et al, 2008; Jubelt et al, 2008). The cholinesterase inhibitor galantamine (Dyer et al, 2008; Sacco et al, 2008) and DMXB-A, a partial α7-nAChR agonist, had limited pro-cognitive effects in non-smokers with schizophrenia (Olincy et al, 2006; Freedman et al, 2008)…”

Section: Discussionmentioning

confidence: 99%

“…The majority of the data (~70% of sample) were derived from a study of the effects of cigarette smoking on cognitive function in schizophrenia, and the role of nicotinic acetylcholine receptors, conducted at Yale University (Sacco et al, 2005; Sacco et al, 2006); the remainder of the data (~30% of the sample) were derived from a cross-sectional study of cognitive function in smokers and non-smokers with schizophrenia at the Centre for Addiction and Mental Health (CAMH), Toronto. Patients with schizophrenia were recruited from clinician referrals and flyers; controls were recruited from the community using newspaper and internet advertisements.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status

Wing

Bacher

Sacco

et al. 2011

Psychiatry Research

View full text Add to dashboard Cite

Schizophrenia is associated with many neurocognitive deficits, some of which are improved by nicotine and cigarette smoking. To better understand the relationship between smoking and cognitive function in schizophrenia, cross-sectional assessment of neuropsychological performance as a function of smoking status (smoker or non-smoker) and smoking history (current, former or never-smoker) in clinically-stable outpatients with schizophrenia and controls was evaluated. Subjects (N=140) were divided into subgroups on the basis of self-report and biochemical verification of smoking history. Current smokers with schizophrenia (n=38), former smokers with schizophrenia (n=17), never-smokers with schizophrenia (n=12), control smokers (n=31), control former smokers (n=16), and control never-smokers (n=26) were administered a comprehensive neuropsychological battery. Smokers were studied under non-deprivation conditions. Comparison of neuropsychological performance in schizophrenia and control subjects revealed significant main effects of diagnosis. Analysis of the data as a function of smoking history demonstrated that never-smokers with schizophrenia performed the poorest on measures of sustained attention, processing speed and response inhibition, when compared to the other schizophrenia subgroups. Cigarette smoking did not alter neuropsychological performance in controls. Our findings suggest that smoking status and history differentially alters neuropsychological outcomes in schizophrenia compared to non-psychiatric controls, and that never-smokers may present with more severe neurocognitive impairments.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status

Wing

Bacher

Sacco

et al. 2011

Psychiatry Research

View full text Add to dashboard Cite

show abstract

“…The reasons for widespread smoking in schizophrenia are not well understood, but these patients may be attempting to reduce the side effects of antipsychotic medications to alleviate negative symptoms and/or cognitive deficits associated with schizophrenia (Kumari and Postma 2005;Sacco et al 2005Sacco et al , 2006, suggesting that cigarette smoking or nicotine serves as a form of self-medication (Leonard et al 2007;Mobascher and Winterer 2008;Winterer 2010).…”

Section: Introductionmentioning

confidence: 99%

Nicotine dependence and serum BDNF levels in male patients with schizophrenia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The primary cognitive outcomes have been reported elsewhere (see Fonder et al, 2005;Sacco et al, 2005;Sacco et al, 2006;George et al, 2006). The aims of this study were to compare biochemical and behavioral indices of cigarette smoking in smokers with and without schizophrenia: 1) at smoking baseline, and; 2) while undergoing acute abstinence and reinstatement in a controlled human laboratory setting.…”

Section: Introductionmentioning

confidence: 99%

Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia

Weinberger

Sacco

Creeden

et al. 2007

Schizophrenia Research

View full text Add to dashboard Cite

Background: Schizophrenics have higher rates of smoking than the general population, and more difficulty with smoking cessation. However, there has been little study of differences between schizophrenics and controls with respect to biochemical and behavioral indices of smoking. We compared smokers with schizophrenia (SS; n=27) and control smokers (CS; n=26) on smoking and psychiatric outcomes at baseline, during acute smoking abstinence and reinstatement, and with pretreatment using the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (MEC) in a human laboratory setting. Methods:Biochemical (e.g., plasma nicotine) and behavioral (e.g., craving, withdrawal) outcomes were assessed at baseline, after overnight abstinence, and after smoking reinstatement during three consecutive test weeks. Each week, participants received one of three doses of MEC (0.0, 5.0, or 10.0 mg/day × 3 days) in a randomized, counterbalanced manner.

show abstract

Neuropsychological deficits in nonsmokers with schizophrenia: Effects of a nicotinic antagonist

Cited by 23 publications

References 31 publications

Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status

Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status

Nicotine dependence and serum BDNF levels in male patients with schizophrenia

Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia

Contact Info

Product

Resources

About